

1 **Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua**

2 Federico Narvaez^{1,2}, Carlos Montenegro², Jose Guillermo Juarez², José Victor Zambrana^{2,3}, Karla
3 Gonzalez^{2,4}, Elsa Videa², Sonia Arguello², Fanny Barrios^{1,2}, Sergio Ojeda², Miguel Plazaola², Nery
4 Sanchez², Daniel Camprubí-Ferrer^{5a}, Guillermina Kuan⁶, Gabriela Paz Bailey⁵, Eva Harris⁷, Angel
5 Balmaseda^{2,4}

6
7 ¹Unidad de Infectología, Hospital Infantil Manuel de Jesús Rivera, Ministerio de Salud, Managua,
8 Nicaragua

9 ²Sustainable Sciences Institute, Managua, Nicaragua

10 ³Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA

11 ⁴Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud,
12 Managua, Nicaragua

13 ⁵Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious
14 Diseases, San Juan, Puerto Rico

15 ⁶Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

16 ⁷Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley,
17 Berkeley, CA

18

19 ^aCurrent affiliation: ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain

20 Section: Vector-borne Diseases or Global Health and Neglected Tropical Diseases

21

22 Corresponding author: Angel Balmaseda, abalmaseda40@gmail.com

23

24 **Summary:** Dengue, a major public health threat, is a viral infection spread by mosquitoes that can cause
25 a range of symptoms from mild to life-threatening. Our study analyzed 19 years of data from two pediatric
26 studies in children 2 to 17 years of age in Managua, Nicaragua. We aimed to understand how dengue
27 severity varies with different serotypes of dengue virus (DENV1-4) and whether the child had a previous
28 dengue infection. We found that DENV2 and DENV3 caused the most severe disease in children. DENV3
29 lead to severe outcomes in both primary (first-time) and secondary (repeat) infections, while DENV2 is
30 particularly severe in secondary infections. These findings highlight the importance of a balanced dengue
31 vaccine that can protect against all four virus strains, as current vaccines show varying effectiveness. Our
32 research emphasizes the need for effective prevention and treatment strategies to manage dengue,
33 particularly in regions where the virus is widespread.

34

35 **Keywords:** dengue, serotype, disease severity, immune status, pediatric, Nicaragua

36 **Abstract**

37 **Background.** Dengue virus, a major global health threat, consists of four serotypes (DENV1-4) that cause
38 a range of clinical manifestations from mild to severe and potentially fatal disease.

39 **Methods.** This study, based on 19 years of data from the Pediatric Dengue Cohort Study and Pediatric
40 Dengue Hospital-based Study in Managua, Nicaragua, investigates the relationship of serotype and
41 immune status with dengue severity. Dengue cases were confirmed by molecular, serological, and/or
42 virological methods, and study participants 6 months to 17 years old were followed during their hospital
43 stay or as ambulatory patients.

44 **Results.** We enrolled a total of 15,266 participants, of whom 3,227 (21%) were positive for DENV
45 infection. Of 2,630 cases with serotype result by RT-PCR, 557 corresponded to DENV1, 992 to DENV2, 759
46 to DENV3 and 322 to DENV4. Severe disease was more prevalent among secondary DENV2 and DENV4
47 cases, while similar disease severity was observed in both primary and secondary DENV1 and DENV3 cases.
48 According to the 1997 World Health Organization (WHO) severity classification, both DENV2 and DENV3
49 caused a higher proportion of severe disease compared to other serotypes, whereas DENV3 caused the
50 greatest percentage of severity according to the WHO-2009 classification. DENV2 was associated with
51 increased odds of pleural effusion and low platelet count, while DENV3 was associated with both
52 hypotensive and compensated shock.

53 **Conclusions.** These findings demonstrate differences in dengue severity by serotype and immune status
54 and emphasize the critical need for a dengue vaccine with balanced effectiveness against all four
55 serotypes, particularly as existing vaccines show variable efficacy by serotype and serostatus.

56

57 **Introduction**

58 The four serotypes of dengue virus (DENV1-4), a mosquito-borne *Flavivirus*, affect tens of millions of
59 people worldwide [1]. In recent decades, dengue epidemics have consistently increased in tropical and
60 subtropical regions of the world, with vector control as the principal means of prevention due to the lack
61 of an effective, widely used vaccine. Dengue viruses cause a range of clinical manifestations, from mild
62 to severe and potentially fatal [2]. Understanding the contribution of serotype and immune status
63 (primary versus secondary DENV infection) to clinical spectrum and severe disease is important for
64 developing effective prevention and control strategies, particularly when introducing new vaccines with
65 differential efficacy [3,4].

66
67 Developing a dengue vaccine has been challenging, primarily because it needs to provide protection
68 against all four DENV serotypes, as imbalanced protection may result in antibody-dependent
69 enhancement of infection and disease [5,6]. The two approved dengue vaccines vary in efficacy by
70 serotype and immune status. Specifically, Dengvaxia® shows low efficacy for DENV2 and results in
71 increased risk of hospitalization when administered to DENV-naïve recipients [7]; QDenga® has low
72 efficacy against DENV3 in dengue-naïve children and unknown efficacy against DENV4 [8]. Thus,
73 understanding how dengue severity is modulated by serotype and immune status is critical for public
74 health policy makers. Several studies have addressed this question, most using the 1997 World Health
75 Organization (WHO) severity classification, with only a handful using the 2009 WHO definitions for severe
76 dengue (SD) [9–13]. These studies showed that both DENV2 and DENV3 are associated with the greatest
77 clinical severity [10,14–17]. A previous analysis of our hospital-based study in Nicaragua also showed that
78 DENV2 cases had a higher frequency of shock and internal hemorrhage when compared to DENV1 cases
79 [18]. However, a comprehensive understanding of how dengue severity varies by serotype and immune
80 status remains limited, especially in Latin America compared to other regions like Southeast Asia [10,15–
81 17].

82
83 For the past 19 years, we have conducted studies on the diagnosis, classification, and clinical management
84 of dengue in Managua, Nicaragua [18–23]. Here we describe the clinical features and severity of dengue
85 cases stratified by serotype and immune status in almost 3,000 patients presenting to our study health
86 center or hospital and followed over the entire course of illness. We analyze primary and secondary cases
87 of all four DENV serotypes classified by both the 1997 and 2009 WHO guidelines.

88 89 **Methods**

90 **Study design.** We leveraged two ongoing studies in Managua: the Pediatric Dengue Cohort Study (PDCS;
91 2004 to present) and the Pediatric Dengue Hospital-based study (PDHS; 2005 to present). The PDCS is the
92 longest ongoing prospective dengue cohort study, currently in its 20th year, following ~4,000 children aged
93 2-17 years old (y/o) in a community-based context, with enhanced passive surveillance at the Health
94 Center Sócrates Flores Vivas (HCSFV) in District 2 of Managua [24]. To maintain the age structure of the
95 PDCS, 200-300 new 2-y/o children are enrolled every year, along with an additional ~200 children 3-7 y/o
96 to compensate for loss to follow-up [24]. The PDHS is a clinical study that enrolls patients every year
97 during the dengue season at the Hospital Infantil Manuel de Jesus Rivera (HIMJR), Nicaragua's national
98 pediatric reference hospital. The PDHS enrolls children from 6 months to 14 y/o with symptoms and signs

99 suggestive of an arbovirus infection (WHO 1997) [25] either in the emergency room or in the Infectious
100 Diseases Unit of the HIMJR [20] Children in the PDCS who require hospitalization are referred to the HIMJR,
101 including patients 15-17 y/o. All participants were followed for their entire course of illness. Both the
102 HCSFV and the HIMJR provide free health care services. Here, we present information from patients
103 enrolled in both studies from September 2004 to February 2023.

104 **Classification of dengue disease severity.** Dengue disease severity was defined by the World Health
105 Organization (WHO) guidelines of 1997 (Dengue Fever [DF], Dengue Hemorrhagic Fever [DHF], Dengue
106 Shock Syndrome [DSS]) [25] and 2009 (Dengue without Warning Signs [DwoWS], Dengue with Warning
107 Signs [DwWS] and Severe Dengue [SD]) [2]. See Supplementary Table 1 for more details. Here, we defined
108 severe dengue disease as DHF/DSS (1997) or SD (2009).

109
110 **Laboratory methods and dengue diagnostics.** Cell blood counts (CBC) and blood chemistry tests were
111 conducted using a Cell/Dyn Rubi (Abbot) and Biosystems BA 400 (Biosystems) automated system,
112 respectively, and the trend over time in each patient's platelet and hematocrit values was reviewed.
113 Dengue cases were confirmed by: 1) RT-PCR/viral isolation in acute-phase (days 1-6 post-onset of
114 symptoms) samples and/or 2) seroconversion by DENV IgM MAC-ELISA and/or seroconversion or a ≥ 4 -
115 fold increase in total DENV antibody titers as measured by the Inhibition ELISA (iELISA) in paired sera from
116 the acute and early convalescent phase (14-28 days post-onset of symptoms) [26,27]. Viral RNA was
117 initially detected using a nested or semi-nested RT-PCR [28,29] and later using a multiplex Zika-
118 Chikungunya-Dengue (ZCD) real-time RT-PCR (rRT-PCR) [30] followed by serotyping of DENV-positive by
119 multiplex DENV rRT-PCR [31]. Immune status was determined using iELISA in convalescent samples;
120 $< 2,560$ was considered primary infection and $\geq 2,560$ was considered secondary infection [19,26]. Patients
121 for whom it was not possible to identify the immune response were excluded from the analysis.

122
123 **Statistical methods.** Descriptive statistics were used to summarize demographic and dengue case data
124 from the PDCS and PDHS, yielding participant counts, serotype distribution, and incidence data (see
125 Supplementary Figures for a breakdown of all results by study). Incidence and distribution of infections
126 by serotype and year were calculated. In addition, we analyzed severity by serotype using both the 1997
127 and 2009 WHO classifications, reporting the distribution of primary and secondary DENV infections and
128 the severity classifications by each serotype in raw numbers and percentages. To analyze severity based
129 on the 1997 and 2009 WHO dengue classifications by serotype and immune status, we used marginal
130 effects from multivariate logistic regressions, producing predictive percentages of severe cases by
131 serotype and immune status and applying an interaction term by serotype and immune status, controlling
132 for age and sex.

133
134 We implemented separate logistic regression models adjusting by immune status to calculate the odds
135 ratios of each symptom and sign by serotype, using DENV1 as the reference value. The signs and
136 symptoms comprised a range of clinical indicators including hypotensive shock, compensated shock, poor
137 capillary refill, pleural effusion, hemoconcentration, low platelet counts, mucosal bleeding, intensive care
138 unit (ICU) admission, inotropic drug usage, abdominal pain, vomiting, rash, headache, and myalgia. All

139 analyses were performed in R version 4.2.2 (R core Team). All the analysis and figures were also stratified
140 by study (PDCS and PDHS) (Supplementary Figures 2-9).

141

142 **Ethics**

143 The PDCS and PDHS were approved by the Institutional Review Boards of the Nicaraguan Ministry of
144 Health (Protocol #CIRE-09/03/07-008.Ver24 and CIRE-01/10/06-13.ver8, respectively) and the UC
145 Berkeley Committee for the Protection of Human Subjects (Protocols 2010-09-2245 and 2010-06-1649,
146 respectively). Informed consent was obtained from all parents or legal guardians before enrollment;
147 assent was obtained from children 6 years of age and older.

148

149 **Results**

150 **Demographic data and dengue cases.** This study includes 15,266 participants, of whom 3,227 were
151 positive for DENV infection. Yearly enrollment (PDHS) or community-based dengue cases (PDCS) varied
152 depending on the epidemic season, with a maximum of 1,751 children in 2019, a minimum of 37 children
153 in 2004, and an average of 101 (Standard Deviation = 82) children per year combining both studies. Of the
154 3,227 dengue cases, 2,738 were DENV-positive by RT-PCR. Of these, the immune response was
155 determined in 2,630 patients; only the latter were analyzed. As a result, 557 DENV1, 992 DENV2, 759
156 DENV3, and 322 DENV4 cases were identified (Table 1). Children were distributed evenly by sex, with
157 1,290 (50%) females, and the average age of disease onset was 9 years in both studies (PDCS= 9.5 y/o,
158 PDHS= 9.0 y/o) (Table 1). Children were followed throughout the course of disease and were managed as
159 inpatients (mean hospitalization = 4.3 days) or outpatients (mean follow-up = 2.2 days) depending on
160 disease severity. Of the 1,286 DENV-positive participants in the PDCS, 439 (34%) required hospitalization
161 following national guidelines and were transferred to the study hospital.

162

163 **DENV serotype and immune status.** Over the 19 years of the studies, we observed varying patterns of
164 circulating DENV serotypes. DENV2 and DENV3 were the most common serotypes, with predominantly
165 secondary infections for DENV2 and similar numbers of primary and secondary infections for DENV3
166 (Figure 1). Similar trends were observed in the PDCS and PDHS (Supplementary Figure 1). Interestingly,
167 after 5 years of only DENV2 cases followed by 2 years of COVID-19 travel restrictions, in 2022, we
168 experienced epidemic levels of DENV4 for the first time in 30 years and simultaneous circulation of all four
169 serotypes. Overall, we observed 905 primary infections and 1,725 secondary infections, with primary
170 infections being most frequent in the ages of 6-10 years and secondary infections most prevalent in ages
171 11-14 years, with an almost equal distribution by sex (Table 2).

172

173 **Dengue severity by immune status and serotype.** The clinical spectrum caused by each serotype was
174 analyzed based on the 1997 and 2009 WHO definitions [2,25]. Using the 1997 classification, 2,212 (84%)
175 patients were DF and 418 (16%) were DHF/DSS (Table 3). Here, severity was defined as DHF/DSS. Using
176 WHO-2009, 1,522 (58%) patients were classified as DwWS and 438 (17%) with SD; therefore, severity was
177 defined as SD (Table 3). Evaluating immune status, we observed that secondary cases were much more
178 prevalent in severe disease caused by DENV2 infections (WHO-1997: 208 [95%] and WHO-2009: 125 [89%])
179 and DENV4 infections (WHO-1997: 10 [100%] and WHO-2009: 9 [82%]), while for DENV1 (WHO-1997: 27
180 [64%] secondary and WHO-2009: 50 [59%] secondary) and DENV3 (WHO-1997: 88 [61%] secondary and

181 WHO-2009: 101 [50%] secondary), disease severity was observed in both primary and secondary
182 infections (Table 3, Figure 2). Similar trends were observed in the PDCS and PDHS (Supplementary Figure
183 2). Evaluating by serotype, we found that DENV3 was associated with the greatest severity in both primary
184 and secondary infections according to both 1997 and 2009 WHO classifications, while DENV2 was most
185 associated with DHF/DSS in secondary cases (Table 3 and model-derived estimates compared to DENV1
186 in Figure 3 and Supplementary Figure 3).

187
188 **Clinical signs and symptoms by serotype.** Compared to DENV1, patients with DENV2 had greater odds of
189 ICU admission (Odds Ratio [OR] 2.29, 95% confidence interval [CI]: 1.25-4.51), hemoconcentration
190 (OR=4.86, 2.09-14.20), low platelet count (OR=1.63, 1.26-2.12 for <100,000 and OR=2.96, 1.95-4.64 for
191 <50,000), pleural effusion (OR=2.94, 2.18-4.00), and mucosal bleeding (OR=1.53, 1.05-2.28), the last only
192 in secondary infections (Figure 4 and Supplementary Figure 8). We also observed a higher risk of rash
193 (OR=1.82, 1.46-2.28) and fewer cases reporting headache (OR= 0.46, 0.36-0.58) and myalgia (OR=0.71,
194 0.56-0.90) compared to DENV1 (Figure 5). For DENV3, we observed a greater association with general
195 symptoms such as rash (OR=2.96, 2.32-3.77) and myalgia (OR=1.59, 1.25-2.01) and alarm signs such as
196 abdominal pain (OR=2.81, 2.18-3.65) and mucosal bleeding (OR=1.86, 1.39-2.51) (Figure 5). In terms of
197 severity, DENV3 was correlated with pleural effusion (OR=2.49, 1.83-3.43), poor capillary refill (OR=2.08,
198 1.55-2.81), compensated shock (OR=2.31, 1.70-3.19), and hypotensive shock (OR=2.17, 1.45-3.34) (Figure
199 4). See Supplementary Figures 4-9 stratified by immune status and study.

200
201 Severe dengue cases, defined by the WHO-2009 criteria, were primarily characterized by shock. The
202 WHO-2009 definition encompasses both compensated and hypotensive shock, unlike the WHO-1997 DSS
203 definition, which includes only cases with hypotensive shock. Table 4 depicts patients identified upon
204 admission with either compensated or hypotensive shock and those progressing from compensated to
205 hypotensive shock, regardless of medical intervention. Notably, the severity of DENV1 is characterized by
206 compensated shock, with only 12 (14%) of patients progressing from compensated to hypotensive shock,
207 in contrast to DENV2 and DENV3, where more cases presented with hypotensive shock (30 [23%] and 24
208 [12%], respectively) or progressed from compensated to hypotensive shock (42 [33%] or 72 [37%],
209 respectively). Further, other symptoms indicative of plasma leakage, such as pleural effusion and ascites,
210 were higher in DENV2 cases (32% and 40%, respectively) and DENV3 cases (25% and 24%, respectively)
211 compared to DENV1 cases (11% and 13%, respectively) (Figures 4 and 5 and Supplementary Figures 4-9
212 stratified by immune status and study). ICU admission was higher in DENV2 (11%) and DENV3 (8%) cases
213 and lower in DENV1 cases (4%). Laboratory abnormalities such as hemoconcentration and
214 thrombocytopenia were more common in DENV2 (6% and 42%, respectively) and lower in DENV1 (1% and
215 25%) and DENV3 (1% and 29%).

216 217 **Discussion**

218 Dengue virus continues to expand globally, with multiple serotypes co-circulating that cause a wide range
219 of clinical outcomes and can be potentially fatal. To evaluate how disease severity is modulated by
220 immune status and DENV serotype, we leveraged two complementary long-term studies in Nicaragua,
221 including an integrated follow-up system from primary health center to hospital, based on 19 years of
222 data. We used both the 1997 and 2009 WHO severity classification schemes, revealing important

223 distinctions. Overall, we found that DENV2 and DENV3 caused the highest percent of DHF/DSS, and
224 DENV3 caused the highest percent of SD, as well as the greatest number of severe clinical manifestations.
225 DENV2 severity occurred primarily in secondary cases, while DENV3 induced severity in primary and
226 secondary infections. This is consistent with previous publications [9,10,15–17,32–35] and of concern
227 given that currently approved vaccines have poor efficacy against DENV2 for Dengvaxia® and DENV3 for
228 QDenga® vaccines in dengue-naïve recipients [7,8].

229
230 When analyzing immune status by serotype, we found that secondary cases predominated for DENV2 and
231 DENV4, whereas more similar numbers of primary and secondary cases were observed for DENV1 and
232 DENV3, again supported by the literature [18,32,36,37]. Even in younger age groups, DENV2 and DENV4
233 showed a higher percentage of secondary cases, suggesting that primary infections by these serotypes
234 were asymptomatic, consistent with previous reports [9,16,32,38,39]. Likewise, severe disease occurred
235 much more often in secondary DENV2 and DENV4 cases, in contrast to DENV1 and DENV3 severe cases,
236 which were more evenly distributed among primary and secondary cases, as reported elsewhere as well
237 [9,17,36,38–42].

238
239 We analyzed the clinical spectrum of dengue considering the two distinct WHO severity classifications of
240 1997 and 2009. The 1997 definition is more focused on the pathophysiology of vascular leak leading to
241 shock, while the 2009 definition aims for real-time identification of clinical disorders to enable timely case
242 management. The clinical spectrum of dengue using the WHO-1997 definition revealed that most dengue
243 cases evolved as DF, regardless of the serotype involved, with approximately 16% being classified as
244 DHF/DSS. In contrast, using the 2009 classification, only 24% of cases evolved as DwoWS, with the
245 majority as DwWS and 17% classified as SD. Sixty-two percent of the patients classified as DHF/DSS (WHO-
246 1997) were classified as DwWS (WHO-2009). All exhibited a clinical profile characterized by plasma
247 leakage and thrombocytopenia that did not progress to shock or respiratory distress.

248
249 Breaking this down by serotype and immune status, secondary cases showed a higher proportion of WHO-
250 1997 severe disease (DHF/DSS), especially in the case of DENV2 for DSS, while DENV3 had a high
251 proportion of DHF/DSS in secondary cases as well as primary cases. Using the WHO-2009 classification,
252 the serotype that exhibited the highest proportion of SD cases was DENV3 for both primary and secondary
253 infections. Overall, DENV2 was associated with severity using the 1997 classification, whereas DENV3
254 exhibited more severe cases according to both 1997 and 2009 definitions. It is important to note that the
255 WHO-1997 DSS definition includes only cases with hypotensive shock, unlike the WHO-2009 SD definition,
256 which encompasses both compensated and hypotensive shock.

257
258 With respect to clinical signs and symptoms, severe thrombocytopenia (<50,000 platelets) was five times
259 more prevalent in DENV2 than in DENV3 cases. Other markers of severity such as hemoconcentration, a
260 sign of plasma leakage, were more common among DENV2 cases, underscoring the importance of this
261 serotype. Both DENV2 and DENV3 were associated with other signs of plasma leakage, while DENV3 was
262 significantly associated with internal and mucosal bleeding.

263

264 Of the WHO-2009 SD cases, two-thirds were not classified as severe by WHO-1997, because they failed to
265 meet the full criteria for DHF/DSS. These were predominantly DENV3 cases (50%) followed by DENV1 and
266 DENV2, almost entirely characterized by some form of shock without thrombocytopenia or hemorrhagic
267 manifestations. Interestingly, most severe cases of DENV1 did not progress to hypotensive shock,
268 maintaining only hemodynamic alterations such as poor capillary refill without advancing to hypotension
269 and/or decreased pulse pressure. This is why DENV1 appears to be more severe than DENV2 when
270 applying the 2009 classification. The severity of both DENV2 and DENV3 is characterized by signs of
271 plasma leakage, resulting in ascites and pleural effusion. However, in comparison with DENV1, DENV3 is
272 significantly associated with hemodynamic alterations leading to shock, either in its initial, compensated
273 stage or during the hypotensive phase. Surprisingly, DENV2 did not have this association with shock,
274 whether compensated or hypotensive, when compared to DENV1. This discrepancy may be attributed to
275 a marked difference in the severity of DENV2 when analyzing immune status, where primary cases evolve
276 favorably.

277
278 Previous reports have also identified that DENV2 (WHO-1997) and DENV3 (WHO-1997 and WHO-2009)
279 account for the greatest dengue severity [9,15,17,43]. A meta-analysis of 170 global dengue outbreaks
280 from 1990 to 2015 ranked DENV2 as the most frequent cause of outbreaks, followed by DENV1, with
281 DENV3 and DENV4 less commonly reported [44]. Importantly, the mortality rates associated with DENV2
282 infections were the highest, followed by DENV3, DENV4, and DENV1 rates. These findings suggest that
283 despite their lower frequency, DENV3 outbreaks are associated with significant disease and mortality.

284
285 One of the key strengths of our study lies in the comprehensive assessment of dengue severity by serotype,
286 utilizing the two WHO classifications from 1997 and 2009. This aspect is particularly important given that
287 most of the literature on dengue severity utilizes the 1997 classification. The introduction of different
288 serotypes into Nicaragua and their varying impacts on disease severity based on which classification is
289 used highlights the importance of future research presenting results using both classification approaches.
290 Another strength is the longitudinal nature of the study with a large number (almost 3,000) of laboratory-
291 confirmed pediatric dengue cases and a single protocol in place for over almost two decades with
292 consistency of clinical care and data collection. Finally, we analyzed community-based and hospital-based
293 cases, as well as those who progressed from the health center to the hospital – made possible by over a
294 decade of careful work by our physicians harmonizing clinical variables between the two sites and a
295 dedicated team of programmers and data managers creating our customized informatics system and
296 algorithm pipelines.

297
298 One limitation of our study was the short circulation time of DENV4, which prevented us from
299 comprehensively analyzing the clinical signs and symptoms of severity in this serotype. Additionally, at
300 the time of this analysis, one lineage of each serotype had circulated in Managua during the study period.
301 Thus, we were not able to compare severity across genotypes or lineages. We plan to expand this analysis
302 following the introduction of new lineages of all the serotypes in 2022 [46].

303
304 Overall, our study reveals that DENV2 and DENV3 consistently lead to the highest severity in dengue cases
305 with certain differences according to WHO classification schema. DENV2 primarily impacts secondary

306 cases, while DENV3 induces severity in primary and secondary infections. These findings highlight the
307 complex interplay between DENV serotypes, immune status and the classifications of disease severity.
308 Moreover, they underscore the need for a vaccine that offers balanced efficacy against all four serotypes.

309

310 **Notes**

311 **Authors contributions.** FN, JGJ, GPB, EH, and AB contributed to the conceptualization of the study. FN, GK,
312 and AB supervised the clinical studies. FN, FB, SO, MP, and NS conducted the studies. KG performed
313 laboratory assays. CM and SA curated the data. JVZ, JGJ, DCF and AB analyzed the data. JGJ, JVZ, DCF, EH,
314 and AB generated the initial figures and tables. FN, JGJ, EH, and AB wrote the initial manuscript draft, and
315 DCF and GPB edited the manuscript. All authors reviewed the manuscript for scientific content.

316

317 **Acknowledgments.** We are grateful to Cesar Narvaez for his contribution to data management for the
318 Pediatric Dengue Hospital-based Study. We thank both past and current team members, based at the
319 Hospital Infantil Manuel de Jesús Rivera, Sócrates Flores Vivas Health Center, the Laboratorio Nacional de
320 Virología in the Centro Nacional de Diagnóstico y Referencia, and the Sustainable Sciences Institute in
321 Nicaragua for their commitment and exceptional work. We are deeply grateful to the participants of the
322 Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study and their families.

323

324 **Financial support.** This work was supported by the National Institute for Allergy and Infectious Diseases
325 (NIAID) of the National Institutes of Health (NIH) grant numbers P01 AI106695 (EH) and R01 AI099631
326 (AB). The studies were supported by P01 AI106695 (EH), U01 AI153416 (EH), U19 AI118610 (EH), U54
327 AI65359 (Barbour; subcontract AB), and BAA-NIAID-DAIT-NIHAI2009061 (Loeb; subcontract AB) from
328 NIAID/NIH, and the the Pediatric Dengue Vaccine Initiative grant VE-1 (EH) and the FIRST grant (EH) from
329 the Bill and Melinda Gates Foundation.

330

331 **Potential conflicts of interest.** The authors declare no conflicts of interest.

332

333 **Data and materials availability.** After securing approval from the UC Berkeley Committee for the
334 Protection of Human Subjects, individual data for figure reproduction can be shared with external
335 researchers. For data access arrangements, please contact E.H. at eharris@berkeley.edu or the CPHS at
336 ophs@berkeley.edu. Standard data transfer agreements govern all data used in this study. The associated
337 code is available at the following link: https://github.com/jgjuarez/Narvaez_Dengue_Clinical_Severity.

338

339 **Disclaimer.** The findings and conclusions in this report are those of the author(s) and do not necessarily
340 represent the views of the Centers for Disease Control and Prevention.

341 **References**

- 342 1. Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global variation
343 in dengue transmission intensity. *Science Translational Medicine* **2020**; 12:eaax4144. Available at:
344 <https://www.science.org/doi/10.1126/scitranslmed.aax4144>.
- 345 2. WHO. Dengue guidelines for diagnosis, treatment, prevention and control : new edition. **2009**;
346 Available at: <https://apps.who.int/iris/handle/10665/44188>.
- 347 3. de Silva A. Safety of Dengue Vaccine? *Clinical Infectious Diseases* **2023**; 76:371–372. Available at:
348 <https://doi.org/10.1093/cid/ciac690>.
- 349 4. Biswal S, Patel SS, Rauscher M. Safety of Dengue Vaccine? *Clin Infect Dis* **2022**; 76:771–772.
350 Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938735/>.
- 351 5. Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. *Microbiology*
352 *Spectrum* **2014**; 2:10.1128/microbiolspec.aid-0022–2014. Available at:
353 <https://journals.asm.org/doi/10.1128/microbiolspec.AID-0022-2014>.
- 354 6. de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be
355 Concerned about Enhanced Disease after Vaccination? *Cold Spring Harb Perspect Biol* **2018**;
356 10:a029371. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983190/>.
- 357 7. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and
358 Efficacy. *N Engl J Med* **2018**; 379:327–340. Available at:
359 <https://www.nejm.org/doi/10.1056/NEJMoa1800820>.
- 360 8. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda’s Dengue Vaccine
361 Candidate (TAK-003). *Clinical Infectious Diseases* **2022**; 75:107–117. Available at:
362 <https://doi.org/10.1093/cid/ciab864>.
- 363 9. Soo K-M, Khalid B, Ching SM, Chee H-Y. Meta-Analysis of Dengue Severity during Infection by
364 Different Dengue Virus Serotypes in Primary and Secondary Infections. *PLOS ONE* **2016**; 11.
- 365 10. Suppiah J, Ching S-M, Amin-Nordin S, et al. Clinical manifestations of dengue in relation to dengue
366 serotype and genotype in Malaysia: A retrospective observational study. *PLoS Negl Trop Dis* **2018**;
367 12:e0006817. Available at: <https://dx.plos.org/10.1371/journal.pntd.0006817>.
- 368 11. Gonçalves BDS, Nogueira RMR, Bispo de Filippis AM, Horta MAP. Factors predicting the severity of
369 dengue in patients with warning signs in Rio de Janeiro, Brazil (1986–2012). *Trans Royal Soc Trop*
370 *Med Hyg* **2019**; 113:670–677. Available at: <https://doi.org/10.1093/trstmh/trz066>.
- 371 12. Dussart P, Baril L, Petit L, et al. Clinical and Virological Study of Dengue Cases and the Members of
372 Their Households: The Multinational DENFRAME Project. *PLoS Negl Trop Dis* **2012**; 6:e1482.
373 Available at: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001482>.
- 374 13. Thomas L, Moravie V, Besnier F, et al. Clinical Presentation of Dengue Among Patients Admitted to
375 the Adult Emergency Department of a Tertiary Care Hospital in Martinique: Implications for Triage,
376 Management, and Reporting. *Annals Emergency Med* **2012**; 59:42–50. Available at:
377 [https://www.annemergmed.com/article/S0196-0644\(11\)01451-X/abstract](https://www.annemergmed.com/article/S0196-0644(11)01451-X/abstract).

- 378 14. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue Viremia Titer, Antibody Response Pattern, and
379 Virus Serotype Correlate with Disease Severity. *J Infect Dis* **2000**; 181:2–9. Available at:
380 <https://doi.org/10.1086/315215>.
- 381 15. Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of dengue
382 hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. *PLoS Negl*
383 *Trop Dis* **2010**; 4:e617.
- 384 16. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997.
385 *Am J Epidemiol* **2000**; 152:804. Available at: <https://doi.org/10.1093/aje/152.9.793>.
- 386 17. Lovera D, Martínez-Cuellar C, Galeano F, Amarilla S, Vazquez C, Arbo A. Clinical manifestations of
387 primary and secondary dengue in Paraguay and its relation to virus serotype. *J Infect Dev Ctries*
388 **2019**; 13:1127–1134. Available at: <https://jids.org/index.php/journal/article/view/11584>.
- 389 18. Balmaseda A, Hammond S, Pérez L, et al. SEROTYPE-SPECIFIC DIFFERENCES IN CLINICAL
390 MANIFESTATIONS OF DENGUE. *Am J Trop Med Hyg* **2006**; 74:449–456. Available at:
391 <https://ajtmh.org/doi/10.4269/ajtmh.2006.74.449>.
- 392 19. Gutiérrez G, Gresh L, Pérez MÁ, et al. Evaluation of the Diagnostic Utility of the Traditional and
393 Revised WHO Dengue Case Definitions. *PLoS Negl Trop Dis* **2013**; 7:e2385. Available at:
394 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002385>.
- 395 20. Narvaez F, Gutierrez G, Pérez MA, et al. Evaluation of the Traditional and Revised WHO
396 Classifications of Dengue Disease Severity. *PLoS Negl Trop Dis* **2011**; 5:e1397. Available at:
397 <https://dx.plos.org/10.1371/journal.pntd.0001397>.
- 398 21. Hammond SN, Balmaseda A, Pérez L, et al. DIFFERENCES IN DENGUE SEVERITY IN INFANTS,
399 CHILDREN, AND ADULTS IN A 3-YEAR HOSPITAL-BASED STUDY IN NICARAGUA. *Am J Trop Med Hyg*
400 **2005**; 73:1063–1070. Available at: [https://www.ajtmh.org/view/journals/tpmd/73/6/article-](https://www.ajtmh.org/view/journals/tpmd/73/6/article-p1063.xml)
401 [p1063.xml](https://www.ajtmh.org/view/journals/tpmd/73/6/article-p1063.xml).
- 402 22. Rocha C, Silva S, Gordon A, et al. Improvement in hospital indicators after changes in dengue case
403 management in Nicaragua. *Am J Trop Med Hyg* **2009**; 81:287–292.
- 404 23. Biswas HH, Ortega O, Gordon A, et al. Early Clinical Features of Dengue Virus Infection in
405 Nicaraguan Children: A Longitudinal Analysis. *PLoS Negl Trop Dis* **2012**; 6:e1562. Available at:
406 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001562>.
- 407 24. Kuan G, Gordon A, Avilés W, et al. The Nicaraguan Pediatric Dengue Cohort Study: Study Design,
408 Methods, Use of Information Technology, and Extension to Other Infectious Diseases. *Am J*
409 *Epidemiol* **2009**; 170:120–129. Available at:
410 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700880/>.
- 411 25. WHO, editor. Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control. 2nd ed.
412 Geneva: World Health Organization, 1997.

- 413 26. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue
414 disease in humans. *Science* **2017**; 358:929–932. Available at:
415 <https://www.science.org/doi/10.1126/science.aan6836>.
- 416 27. Balmaseda A, Sandoval E, Pérez L, Gutiérrez CM, Harris E. Application of molecular typing
417 techniques in the 1998 dengue epidemic in Nicaragua. *Am J Trop Med Hyg* **1999**; 61:893–897.
418 Available at: <https://www.ajtmh.org/view/journals/tpmd/61/6/article-p893.xml>.
- 419 28. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue
420 viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. *J*
421 *Clin Microbiol* **1992**; 30:545–551. Available at: [https://journals.asm.org/doi/10.1128/jcm.30.3.545-](https://journals.asm.org/doi/10.1128/jcm.30.3.545-551.1992)
422 [551.1992](https://journals.asm.org/doi/10.1128/jcm.30.3.545-551.1992).
- 423 29. Harris E, Roberts TG, Smith L, et al. Typing of Dengue Viruses in Clinical Specimens and Mosquitoes
424 by Single-Tube Multiplex Reverse Transcriptase PCR. *J Clin Microbiol* **1998**; 36:2634–2639. Available
425 at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105176/>.
- 426 30. Waggoner JJ, Ballesteros G, Gresh L, et al. Clinical evaluation of a single-reaction real-time RT-PCR
427 for pan-dengue and chikungunya virus detection. *J Clin Virol* **2016**; 78:57–61. Available at:
428 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836994/>.
- 429 31. Waggoner JJ, Abeynayake J, Sahoo MK, et al. Single-Reaction, Multiplex, Real-Time RT-PCR for the
430 Detection, Quantitation, and Serotyping of Dengue Viruses. *PLoS Negl Trop Dis* **2013**; 7:e2116.
431 Available at: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002116>.
- 432 32. Balmaseda A, Standish K, Mercado JC, et al. Trends in Patterns of Dengue Transmission over 4 Years
433 in a Pediatric Cohort Study in Nicaragua. *J Infect Dis* **2010**; 201:5–14. Available at:
434 <https://doi.org/10.1086/648592>.
- 435 33. Sasmono RT, Kalalo LP, Trismiasih S, et al. Multiple introductions of dengue virus strains contribute
436 to dengue outbreaks in East Kalimantan, Indonesia, in 2015–2016. *Virology J* **2019**; 16:93. Available
437 at: <https://doi.org/10.1186/s12985-019-1202-0>.
- 438 34. Thomas L, Najjioullah F, Besnier F, Valentino R, Césaire JRR, Cabié A. Clinical Presentation of Dengue
439 by Serotype and Year of Epidemic in Martinique. *Am J Trop Med Hyg* **2014**; 91:138–145. Available
440 at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080553/>.
- 441 35. Soe AM, Ngwe Tun MM, Nabeshima T, et al. Emergence of a Novel Dengue Virus 3 (DENV-3)
442 Genotype-I Coincident with Increased DENV-3 Cases in Yangon, Myanmar between 2017 and 2019.
443 *Viruses* **2021**; 13:1152. Available at: <https://www.mdpi.com/1999-4915/13/6/1152>.
- 444 36. Harris E, Videz E, Pérez L, et al. Clinical, epidemiologic, and virologic features of dengue in the 1998
445 epidemic in Nicaragua. *Am J Trop Med Hyg* **2000**; 63:5–11. Available at:
446 <https://www.ajtmh.org/view/journals/tpmd/63/1/article-p5.xml>.
- 447 37. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, et al. Sequential dengue virus infections detected in
448 active and passive surveillance programs in Thailand, 1994–2010. *BMC Public Health* **2015**; 15:250.
449 Available at: <https://doi.org/10.1186/s12889-015-1590-z>.

- 450 38. Yung C-F, Lee K-S, Thein T-L, et al. Dengue serotype-specific differences in clinical manifestation,
451 laboratory parameters and risk of severe disease in adults, Singapore. *Am J Trop Med Hyg* **2015**;
452 92:999–1005. Available at: <https://europepmc.org/articles/PMC4426593>.
- 453 39. Zambrana JV, Hasund CM, Aogo RA, et al. Primary exposure to Zika virus is linked with increased
454 risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1. *Sci Transl Med*
455 **2024**; 16:eadn2199. Available at: <https://www.science.org/doi/10.1126/scitranslmed.adn2199>.
- 456 40. BARDE PV, KORI BK, SHUKLA MK, et al. Maiden outbreaks of dengue virus 1 genotype III in rural
457 central India. *Epidemiol Infect* **2015**; 143:412–418. Available at:
458 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206798/>.
- 459 41. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a
460 prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. *Am J Epidemiol* **1984**;
461 120:653–669.
- 462 42. Vuong NL, Quyen NTH, Tien NTH, et al. Dengue viremia kinetics and effects on platelet count and
463 clinical outcomes: An analysis of 2340 patients from Vietnam. *eLife* **2024**; 13:RP92606. Available at:
464 <https://doi.org/10.7554/eLife.92606>.
- 465 43. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic Studies on Dengue in Santiago de Cuba, 1997.
466 *Am J Epidemiol* **2000**; 152:793–799. Available at: <https://doi.org/10.1093/aje/152.9.793>.
- 467 44. Guo C, Zhou Z, Wen Z, et al. Global Epidemiology of Dengue Outbreaks in 1990–2015: A Systematic
468 Review and Meta-Analysis. *Front Cell Infect Microbiol* **2017**; 7. Available at:
469 <https://www.frontiersin.org/articles/10.3389/fcimb.2017.00317>.
- 470

471 **Tables**

472

473

474 **Table 1. Study population: Demographic information, DENV serotype, and health facility, PDCS and**
 475 **PDHS, Managua, Nicaragua, 2004-2023.**

| | Cohort HC¹ only (n= 847) | Hospital (n= 1,344) | Transferred from cohort HC to Hospital (n=439) |
|-----------------|--|--------------------------------|---|
| Age | 9.61 (SD= 3.60) | 9.01 (SD= 3.76) | 10.48 (SD= 3.43) |
| < 1 | 0 (0%) | 31 (2.3%) | 0 (0%) |
| 1 to 5 | 125 (15%) | 236 (17%) | 43 (10%) |
| 6 to 10 | 364 (43%) | 523 (39%) | 162 (37%) |
| 11 to 14 | 278 (33%) | 551 (41%) | 185 (42%) |
| 15 to 17 | 80 (9.5%) | 3 (0.2%) | 49 (11%) |
| sexo | | | |
| F | 441 (52%) | 648 (48%) | 224 (51%) |
| Serotype | | | |
| DENV1 | 201 (25%) | 268 (20%) | 88 (20%) |
| DENV2 | 313 (37%) | 532 (40%) | 147 (33%) |
| DENV3 | 182 (21%) | 451 (34%) | 126 (29%) |
| DENV4 | 151 (18%) | 93 (6.9%) | 78 (18%) |

476 ¹Health Center

477

478 **Table 2. Age distribution of dengue cases by DENV serotype and immune status, PDCS and PDHS,**
 479 **Managua, Nicaragua, 2004-2023.**

| Serotypes | DENV1 | | DENV2 | | DENV3 | | DENV4 | |
|------------------|--------------|--------------|-------------|--------------|--------------|--------------|-------------|--------------|
| | 1° | 2° | 1° | 2° | 1° | 2° | 1° | 2° |
| Age group | | | | | | | | |
| < 1 | 6 (2.1%) | 0 (0%) | 8 (4.7%) | 3 (0.4%) | 12 (3.1%) | 2 (0.5%) | 0 (0%) | 0 (0%) |
| 1 to 5 | 56 (20%) | 11 (4.1%) | 45 (26%) | 93 (11%) | 145 (37%) | 40 (11%) | 6 (10%) | 8 (3.0%) |
| 6 to 10 | 121 (42%) | 103 (38%) | 79 (46%) | 299 (36%) | 172 (44%) | 171 (46%) | 23 (40%) | 81 (31%) |
| 11 to 14 | 100 (35%) | 140 (52%) | 36 (21%) | 389 (47%) | 55 (14%) | 145 (39%) | 17 (29%) | 132 (50%) |
| 15 to 17 | 4 (1.4%) | 16 (5.9%) | 4 (2.3%) | 36 (4.4%) | 4 (1.0%) | 13 (3.5%) | 12 (21%) | 43 (16%) |
| Sex | | | | | | | | |
| F | 136 (47%) | 128 (47%) | 88 (51%) | 395 (48%) | 194 (50%) | 191 (51%) | 35 (60%) | 146 (55%) |
| M | 151 (53%) | 142 (53%) | 84 (49%) | 425 (52%) | 194 (50%) | 180 (49%) | 23 (40%) | 118 (45%) |

480

481 **Table 3. Dengue severity by serotype and immune status using the WHO 1997 and 2009**
 482 **classifications, PDCS and PDHS, Managua, Nicaragua, 2004-2023.**

| Serotypes | DENV1 | | DENV2 | | DENV3 | | DENV4 | |
|-----------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | 1° | 2° | 1° | 2° | 1° | 2° | 1° | 2° |
| WHO-1997 | | | | | | | | |
| DF | 272 (95%) | 243 (90%) | 158 (92%) | 612 (75%) | 332 (86%) | 283 (76%) | 58 (100%) | 254 (96%) |
| DHF | 12 (4.3%) | 21 (7.9%) | 12 (7.1%) | 160 (20%) | 43 (11%) | 72 (19%) | 0 (0%) | 9 (3.5%) |
| DSS | 3 (1.1%) | 6 (2.3%) | 2 (1.2%) | 48 (5.9%) | 13 (3.4%) | 16 (4.3%) | 0 (0%) | 1 (0.4%) |
| WHO-2009 | | | | | | | | |
| DWoWS | 96 (35%) | 89 (34%) | 68 (40%) | 106 (13%) | 71 (18%) | 76 (21%) | 27 (48%) | 102 (40%) |
| DWW | 145 (53%) | 126 (48%) | 85 (51%) | 586 (72%) | 214 (56%) | 193 (52%) | 26 (46%) | 147 (57%) |
| SD | 35 (13%) | 50 (19%) | 15 (8.9%) | 125 (15%) | 100 (26%) | 101 (27%) | 3 (5.4%) | 9 (3.5%) |

483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505

506 **Table 4. Compensated shock and hypotensive shock by DENV serotype.**

| Serotype | Only compensated shock | Only hypotensive shock | Hypotensive from compensated shock |
|-----------------|-------------------------------|-------------------------------|---|
| DENV1 | 52 (62%) | 20 (24%) | 12 (14%) |
| DENV2 | 56 (44%) | 30 (23%) | 42 (33%) |
| DENV3 | 97 (50%) | 24 (12%) | 72 (37%) |
| DENV4 | 2 (22%) | 6 (67%) | 1 (11%) |

507

508 **Figure Legends**

509

510 **Figure 1. DENV circulation by immune status in the PDCS and PDHS combined, Managua, 2004-2022.**

511 Circulating serotypes and immune status in dengue cases in the studies in Managua are represented. The
512 hospital study was not run in 2020 and 2021.

513

514 **Figure 2. Distribution by immune response among severe dengue cases, PDCS and PDHS combined,**
515 **Managua, 2004-2022.**

516

517 **Figure 3. Model-derived severity by DENV serotype of infection and immune status in the PDCS and**
518 **PDHS combined, Managua, 2004-2022.** Model-derived estimates compared to DENV1 stratified by WHO
519 disease severity classification and immune status, as indicated. Model was adjusted by age and sex. Due
520 to sample size, DENV4 was excluded from the analysis. Blue dotted line, DENV1 reference value. IR,
521 immune response.

522


523 **Figure 4. Clinical signs, clinical laboratory results, and case management of dengue severity by serotype**
524 **in both primary and secondary cases in the PDCS and PDHS combined, Managua, 2004-2022.** Mucosal
525 bleeding: epistaxis, gingivorrhagia, conjunctival bleeding, hematuria, hematemesis, melena, vaginal
526 bleeding. ICU, intensive care unit.

527

528 **Figure 5. Symptoms of dengue by serotype in both primary and secondary cases in the PDCS and PDHS**
529 **combined, Managua, 2004-2022.**


530

531 **Figure 1**




532

533 **Figure 2**




534
535

536 **Figure 3**




537
538

539 **Figure 4**



540
541
542

543 **Figure 5**



544
545